Shimon I, Hinton D R, Weiss M H, Melmed S
Department of Medicine, Cedars-Sinai Research Institute, UCLA School of Medicine, USA.
Clin Endocrinol (Oxf). 1998 Jan;48(1):23-9. doi: 10.1046/j.1365-2265.1998.00332.x.
We have shown previously that heparin-binding secretory transforming gene (hst) overexpression in rat pituitary cells mediates lactotroph tumour growth and stimulates PRL transcription, and that transforming sequences of the gene, which encode fibroblast growth factor-4 (FGF-4), are expressed in human prolactinomas. To further determine the role of hst in human PRL-secreting adenoma pathogenesis we studied the presence of hst protein in these tumours and other types of human pituitary adenoma.
Pituitary adenoma tissue samples were obtained at surgery from 14 patients with PRL-secreting adenomas, 5 patients with GH-secreting tumours, 3 with ACTH-secreting, and 13 patients with nonfunctioning tumours. Two normal pituitary tissue specimens were also studied. Clinical data, including tumour invasiveness assessed by preoperative MRI studies, were available. For hst protein immunolocalization, tumour frozen sections were immunostained with antihuman FGF-4 antibody. Immunoperoxidase staining for the proliferation-related nuclear antigen Ki-67 was performed using MIB-1 monoclonal antibody.
Normal anterior pituitary cells did not contain immunoreactive hst protein. Lactotrophs in five of 14 prolactinomas (36%) stained strongly for hst compared with immunoreactive pituicytes in only one of 21 nonfunctioning, GH-, and ACTH-secreting adenomas (P = 0.05). Immunoreactive hst in adenoma cells was detected in 3 of 5 invasive prolactinomas, and in 2 of 9 noninvasive PRL-cell adenomas. Immunostaining for the proliferation-related antigen Ki-67 showed a higher proliferation index in hst-positive adenomas (3.94 + 0.85%) as compared with those immunonegative for hst (1.98 + 0.7%; P = 0.05).
hst protein may be directly involved in prolactinoma development or progression, particularly in invasive tumours, probably due to the growth promoting effects of FGF-4.
我们之前已经表明,大鼠垂体细胞中肝素结合分泌转化基因(hst)的过表达介导催乳素瘤生长并刺激催乳素(PRL)转录,并且该基因编码成纤维细胞生长因子-4(FGF-4)的转化序列在人催乳素瘤中表达。为了进一步确定hst在人PRL分泌性腺瘤发病机制中的作用,我们研究了这些肿瘤以及其他类型人垂体腺瘤中hst蛋白的存在情况。
垂体腺瘤组织样本取自14例PRL分泌性腺瘤患者、5例GH分泌性肿瘤患者、3例ACTH分泌性肿瘤患者以及13例无功能性肿瘤患者的手术切除标本。还研究了两份正常垂体组织标本。可获取临床数据,包括术前MRI检查评估的肿瘤侵袭性。对于hst蛋白免疫定位,肿瘤冰冻切片用抗人FGF-4抗体进行免疫染色。使用MIB-1单克隆抗体进行增殖相关核抗原Ki-67的免疫过氧化物酶染色。
正常垂体前叶细胞不含免疫反应性hst蛋白。14例催乳素瘤中有5例(36%)的催乳素细胞hst染色强烈,而21例无功能性、GH分泌性和ACTH分泌性腺瘤中只有1例的垂体细胞免疫反应性强(P = 0.05)。在5例侵袭性催乳素瘤中有3例检测到腺瘤细胞中的免疫反应性hst,在9例非侵袭性PRL细胞腺瘤中有2例检测到。增殖相关抗原Ki-67的免疫染色显示,hst阳性腺瘤的增殖指数(3.94 + 0.85%)高于hst免疫阴性腺瘤(1.98 + 0.7%;P = 0.05)。
hst蛋白可能直接参与催乳素瘤的发生或进展,特别是在侵袭性肿瘤中,这可能是由于FGF-4的促生长作用。